Sparton Resources Inc

Synfini Secures $8.9 Million to Accelerate AI-Driven Small Molecule Drug Discovery Platform

- Synfini raised $8.9 million in additional funding led by JSL Health Capital, bringing total funding to $53 million to advance its AI Cloud Foundry platform for small molecule drug discovery. - The company's integrated platform combines artificial intelligence, automated synthesis, and iterative molecular design to reduce small molecule iteration cycles from months to days. - Synfini plans to use the funding to expand its software and automated lab capabilities, hire scientific and engineering talent, and grow commercial partnerships in GPCR-targeted therapeutics and precision oncology. - The AI-driven chemistry automation platform eliminates traditional bottlenecks by streamlining target selection, compound design, and synthesis into a unified workflow.